<?xml version="1.0" encoding="UTF-8"?>
<jcr:root xmlns:jcr="http://www.jcp.org/jcr/1.0" xmlns:nt="http://www.jcp.org/jcr/nt/1.0" xmlns:mix="http://www.jcp.org/jcr/mix/1.0" xmlns:cq="http://www.day.com/jcr/cq/1.0" xmlns:sling="http://sling.apache.org/jcr/sling/1.0"
    jcr:primaryType="cq:Page">
    <jcr:content
        cq:lastModified="{Date}2023-04-20T13:34:31.686Z"
        cq:lastModifiedBy="m.papini@adiacent.com"
        cq:lastReplicated="{Date}2023-04-20T13:34:35.022Z"
        cq:lastReplicated_publish="{Date}2023-04-20T13:34:35.022Z"
        cq:lastReplicatedBy="m.papini@adiacent.com"
        cq:lastReplicatedBy_publish="m.papini@adiacent.com"
        cq:lastReplicationAction="Activate"
        cq:lastReplicationAction_publish="Activate"
        cq:redirectPermanent="true"
        cq:template="/conf/menarini-stemline/settings/wcm/templates/menarini---details-page"
        jcr:isCheckedOut="{Boolean}true"
        jcr:mixinTypes="[mix:versionable]"
        jcr:primaryType="cq:PageContent"
        jcr:title="History"
        jcr:uuid="664451b7-3327-4785-8756-5aaa2d4c7e46"
        sling:alias="our-history"
        sling:resourceType="menarinimaster/components/page"
        pwaCachestrategy="staleWhileRevalidate"
        pwaDisplay="standalone"
        pwaOrientation="any">
        <root
            jcr:primaryType="nt:unstructured"
            sling:resourceType="menarinimaster/components/container"
            layout="responsiveGrid">
            <container
                jcr:primaryType="nt:unstructured"
                sling:resourceType="menarinimaster/components/container"
                layout="responsiveGrid">
                <internalheader
                    jcr:lastModified="{Date}2023-04-19T14:07:21.249Z"
                    jcr:lastModifiedBy="m.papini@adiacent.com"
                    jcr:primaryType="nt:unstructured"
                    jcr:title="About us"
                    sling:resourceType="menarinimaster/components/internalheader"
                    disableLazyLoading="false"
                    fileReference="/content/dam/menarini-stemline/assets/header_about_us.jpg"
                    imageFromPageImage="false"
                    isDecorative="true"
                    textIsRich="true"
                    titleFromPage="false"/>
                <breadcrumb
                    jcr:primaryType="nt:unstructured"
                    sling:resourceType="menarinimaster/components/breadcrumb"/>
                <container
                    jcr:primaryType="nt:unstructured"
                    sling:resourceType="menarinimaster/components/container"
                    layout="responsiveGrid">
                    <internalmenu
                        jcr:primaryType="nt:unstructured"
                        sling:resourceType="menarinimaster/components/internalmenu"
                        navigationRoot="/content/menarini-stemline/en/en/about-us"
                        structureStart="{Long}0">
                        <cq:responsive jcr:primaryType="nt:unstructured">
                            <default
                                jcr:primaryType="nt:unstructured"
                                offset="0"
                                width="3"/>
                            <tablet
                                jcr:primaryType="nt:unstructured"
                                offset="0"
                                width="4"/>
                            <phone
                                jcr:primaryType="nt:unstructured"
                                offset="0"
                                width="12"/>
                        </cq:responsive>
                    </internalmenu>
                    <container
                        cq:styleIds="[1655202404538]"
                        jcr:primaryType="nt:unstructured"
                        sling:resourceType="menarinimaster/components/container"
                        layout="responsiveGrid">
                        <title
                            cq:styleIds="[1653552493699]"
                            jcr:lastModified="{Date}2022-07-26T17:40:44.634+02:00"
                            jcr:lastModifiedBy="admin"
                            jcr:primaryType="nt:unstructured"
                            sling:resourceType="menarinimaster/components/title"
                            linkTarget="_self"
                            type="h2">
                            <cq:responsive jcr:primaryType="nt:unstructured">
                                <default
                                    jcr:primaryType="nt:unstructured"
                                    offset="0"
                                    width="5"/>
                            </cq:responsive>
                        </title>
                        <cq:responsive jcr:primaryType="nt:unstructured">
                            <default
                                jcr:primaryType="nt:unstructured"
                                offset="0"
                                width="8"/>
                            <tablet
                                jcr:primaryType="nt:unstructured"
                                offset="0"
                                width="8"/>
                            <phone
                                jcr:primaryType="nt:unstructured"
                                offset="0"
                                width="12"/>
                        </cq:responsive>
                        <accordion
                            jcr:lastModified="{Date}2023-04-19T12:42:14.997Z"
                            jcr:lastModifiedBy="j.kaur@adiacent.com"
                            jcr:primaryType="nt:unstructured"
                            sling:resourceType="menarinimaster/components/accordion"
                            expandedItems="[item_1]"
                            headingElement="h3"
                            singleExpansion="false">
                            <item_1
                                cq:panelTitle="January 2023"
                                jcr:primaryType="nt:unstructured"
                                jcr:title="Item 1"
                                sling:resourceType="menarinimaster/components/container"
                                layout="responsiveGrid">
                                <text
                                    jcr:lastModified="{Date}2023-03-17T10:19:16.559Z"
                                    jcr:lastModifiedBy="m.papini@adiacent.com"
                                    jcr:primaryType="nt:unstructured"
                                    sling:resourceType="menarinimaster/components/text"
                                    text="&lt;p>&lt;b>ORSERDU™ (elacestrant) &lt;/b>approved by the U.S. FDA as the First and Only Treatment Specifically Indicated for Patients with ESR1 Mutations in ER+, HER2- Advanced or Metastatic Breast Cancer with disease progression following at least one line of endocrine therapy.&lt;/p>&#xd;&#xa;"
                                    textIsRich="true"/>
                            </item_1>
                            <item_2
                                cq:panelTitle="August 2022"
                                jcr:lastModified="{Date}2023-03-17T10:20:23.638Z"
                                jcr:lastModifiedBy="m.papini@adiacent.com"
                                jcr:primaryType="nt:unstructured"
                                jcr:title="Item 2"
                                sling:resourceType="menarinimaster/components/container"
                                layout="responsiveGrid">
                                <text
                                    jcr:lastModified="{Date}2023-03-16T08:42:44.640Z"
                                    jcr:lastModifiedBy="m.papini@adiacent.com"
                                    jcr:primaryType="nt:unstructured"
                                    sling:resourceType="menarinimaster/components/text"
                                    text="&lt;p>Elacestrant, the first oral SERD for HR+/HER2- advanced or metastatic breast cancer with positive Phase 3 data, granted priority review by the U.S. FDA&lt;/p>&#xd;&#xa;&lt;p>Elacestrant marketing authorization application accepted for review by the EMA for the treatment of HR+/HER2– advanced or metastatic breast cancer&lt;/p>&#xd;&#xa;"
                                    textIsRich="true">
                                    <cq:responsive jcr:primaryType="nt:unstructured">
                                        <default
                                            jcr:primaryType="nt:unstructured"
                                            offset="0"
                                            width="8"/>
                                        <phone
                                            jcr:primaryType="nt:unstructured"
                                            offset="0"
                                            width="12"/>
                                    </cq:responsive>
                                </text>
                            </item_2>
                            <item_1678203925125
                                cq:panelTitle="July 2022"
                                jcr:primaryType="nt:unstructured"
                                sling:resourceType="menarinimaster/components/container">
                                <text
                                    jcr:lastModified="{Date}2023-03-09T13:02:55.823Z"
                                    jcr:lastModifiedBy="m.papini@adiacent.com"
                                    jcr:primaryType="nt:unstructured"
                                    sling:resourceType="menarinimaster/components/text"
                                    text="&lt;p>The European Commission granted marketing authorization for NEXPOVIO in combination with once-weekly bortezomib and low-dose dexamethasone in multiple myeloma.&lt;/p>&#xd;&#xa;&lt;p>The Menarini Group obtained global licensing rights from Radius Health, Inc, for elacestrant—a selective estrogen receptor degrader (SERD) for patients with hormone receptor–positive (HR+)/human epidermal growth factor receptor 2–negative (HER2–) advanced or metastatic breast cancer&lt;/p>&#xd;&#xa;"
                                    textIsRich="true"/>
                            </item_1678203925125>
                            <item_1678203953349
                                cq:panelTitle="December 2021"
                                jcr:primaryType="nt:unstructured"
                                sling:resourceType="menarinimaster/components/container">
                                <text
                                    jcr:lastModified="{Date}2023-03-09T13:01:53.598Z"
                                    jcr:lastModifiedBy="m.papini@adiacent.com"
                                    jcr:primaryType="nt:unstructured"
                                    sling:resourceType="menarinimaster/components/text"
                                    text="&lt;p>Karyopharm and Menarini entered into an exclusive licensing agreement whereby Menarini is responsible for commercializing all current and future indications of NEXPOVIO® (selinexor) in the European Economic Area, United Kingdom, Switzerland, CIS countries, Turkey, and Latin America. Stemline Therapeutics B.V., a wholly owned subsidiary of Menarini, is leading all commercialization activities in Europe&lt;/p>&#xd;&#xa;"
                                    textIsRich="true"/>
                            </item_1678203953349>
                            <item_1678203967261
                                cq:panelTitle="January 2021"
                                jcr:primaryType="nt:unstructured"
                                sling:resourceType="menarinimaster/components/container">
                                <text
                                    jcr:lastModified="{Date}2023-03-09T13:01:15.932Z"
                                    jcr:lastModifiedBy="m.papini@adiacent.com"
                                    jcr:primaryType="nt:unstructured"
                                    sling:resourceType="menarinimaster/components/text"
                                    text="&lt;p>ELZONRIS approved by the EMA as monotherapy for the first-line treatment of adult patients with BPDCN&lt;/p>&#xd;&#xa;"
                                    textIsRich="true"/>
                            </item_1678203967261>
                            <item_1678203976268
                                cq:panelTitle="January 2020"
                                jcr:primaryType="nt:unstructured"
                                sling:resourceType="menarinimaster/components/container">
                                <text
                                    jcr:lastModified="{Date}2023-03-09T13:00:43.213Z"
                                    jcr:lastModifiedBy="m.papini@adiacent.com"
                                    jcr:primaryType="nt:unstructured"
                                    sling:resourceType="menarinimaster/components/text"
                                    text="&lt;p>Stemline acquired by the Menarini Group&lt;/p>&#xd;&#xa;"
                                    textIsRich="true"/>
                            </item_1678203976268>
                            <item_1678203993380
                                cq:panelTitle="December 2018"
                                jcr:primaryType="nt:unstructured"
                                sling:resourceType="menarinimaster/components/container">
                                <text
                                    jcr:lastModified="{Date}2023-03-09T13:00:08.100Z"
                                    jcr:lastModifiedBy="m.papini@adiacent.com"
                                    jcr:primaryType="nt:unstructured"
                                    sling:resourceType="menarinimaster/components/text"
                                    text="&lt;p>ELZONRIS monotherapy became the first U.S. FDA-approved and commercially available treatment for adult and pediatric patients, 2 years or older, with BPDCN&lt;/p>&#xd;&#xa;"
                                    textIsRich="true"/>
                            </item_1678203993380>
                            <item_1678204039864
                                cq:panelTitle="November 2018"
                                jcr:primaryType="nt:unstructured"
                                sling:resourceType="menarinimaster/components/container">
                                <text
                                    jcr:lastModified="{Date}2023-03-09T12:59:31.124Z"
                                    jcr:lastModifiedBy="m.papini@adiacent.com"
                                    jcr:primaryType="nt:unstructured"
                                    sling:resourceType="menarinimaster/components/text"
                                    text="&lt;p>ELZONRIS granted accelerated assessment for the Marketing Authorization Application (MAA) by the European Medicines Agency (EMA).&lt;/p>&#xd;&#xa;"
                                    textIsRich="true"/>
                            </item_1678204039864>
                            <item_1678204054488
                                cq:panelTitle="August 2016"
                                jcr:primaryType="nt:unstructured"
                                sling:resourceType="menarinimaster/components/container">
                                <text
                                    jcr:lastModified="{Date}2023-03-09T12:58:54.824Z"
                                    jcr:lastModifiedBy="m.papini@adiacent.com"
                                    jcr:primaryType="nt:unstructured"
                                    sling:resourceType="menarinimaster/components/text"
                                    text="&lt;p>ELZONRIS granted breakthrough therapy designation by the U.S. Food and Drug Administration (FDA) &lt;/p>&#xd;&#xa;"
                                    textIsRich="true"/>
                            </item_1678204054488>
                            <item_1678204066124
                                cq:panelTitle="November 2015"
                                jcr:primaryType="nt:unstructured"
                                sling:resourceType="menarinimaster/components/container">
                                <text
                                    jcr:lastModified="{Date}2023-03-09T12:58:19.723Z"
                                    jcr:lastModifiedBy="m.papini@adiacent.com"
                                    jcr:primaryType="nt:unstructured"
                                    sling:resourceType="menarinimaster/components/text"
                                    text="&lt;p>ELZONRIS granted ODD for the treatment of BPDCN in Europe&lt;/p>&#xd;&#xa;"
                                    textIsRich="true"/>
                            </item_1678204066124>
                            <item_1678204078704
                                cq:panelTitle="June 2013"
                                jcr:primaryType="nt:unstructured"
                                sling:resourceType="menarinimaster/components/container">
                                <text
                                    jcr:lastModified="{Date}2023-03-09T12:57:41.337Z"
                                    jcr:lastModifiedBy="m.papini@adiacent.com"
                                    jcr:primaryType="nt:unstructured"
                                    sling:resourceType="menarinimaster/components/text"
                                    text="&lt;p>ELZONRIS®&amp;nbsp;(tagraxofusp), a therapy targeting CD123, granted orphan drug designation (ODD) for the treatment of blastic plasmacytoid dendritic cell neoplasm (BPDCN) in the U.S.&lt;/p>&#xd;&#xa;"
                                    textIsRich="true"/>
                            </item_1678204078704>
                            <item_1678204090792
                                cq:panelTitle="August 2003"
                                jcr:primaryType="nt:unstructured"
                                sling:resourceType="menarinimaster/components/container">
                                <text
                                    jcr:lastModified="{Date}2023-03-09T12:57:04.738Z"
                                    jcr:lastModifiedBy="m.papini@adiacent.com"
                                    jcr:primaryType="nt:unstructured"
                                    sling:resourceType="menarinimaster/components/text"
                                    text="&lt;p>Stemline founded in New York City with the mission of identifying and developing novel therapeutics for difficult-to-treat cancers&lt;/p>&#xd;&#xa;"
                                    textIsRich="true"/>
                            </item_1678204090792>
                        </accordion>
                        <spacer
                            jcr:lastModified="{Date}2023-03-28T08:25:06.350Z"
                            jcr:lastModifiedBy="m.papini@adiacent.com"
                            jcr:primaryType="nt:unstructured"
                            sling:resourceType="menarinimaster/components/spacer"
                            spacer="30"/>
                    </container>
                    <spacer_copy
                        jcr:lastModified="{Date}2023-04-20T13:34:31.680Z"
                        jcr:lastModifiedBy="m.papini@adiacent.com"
                        jcr:primaryType="nt:unstructured"
                        sling:resourceType="menarinimaster/components/spacer"
                        spacer="40"/>
                    <container_197822381
                        cq:styleIds="[1655202404538]"
                        jcr:lastModified="{Date}2023-04-14T07:51:33.392Z"
                        jcr:lastModifiedBy="m.papini@adiacent.com"
                        jcr:primaryType="nt:unstructured"
                        sling:resourceType="menarinimaster/components/container">
                        <container_copy_copy
                            jcr:lastModified="{Date}2023-04-14T07:51:59.318Z"
                            jcr:lastModifiedBy="m.papini@adiacent.com"
                            jcr:primaryType="nt:unstructured"
                            sling:resourceType="menarinimaster/components/container"
                            layout="responsiveGrid">
                            <card_copy_copy
                                jcr:description="&lt;p>Our executive team helps ensure that quality always comes first.&lt;/p>&#xd;&#xa;"
                                jcr:lastModified="{Date}2023-04-20T13:19:46.314Z"
                                jcr:lastModifiedBy="m.papini@adiacent.com"
                                jcr:primaryType="nt:unstructured"
                                jcr:title="Our Leadership"
                                sling:resourceType="menarinimaster/components/card"
                                descriptionFromPage="false"
                                disableLazyLoading="false"
                                fileReference="/content/dam/menarini-stemline/assets/history-int.jpg"
                                imageFromPageImage="false"
                                isDecorative="true"
                                linkTarget="_self"
                                linkURL="/content/menarini-stemline/en/en/about-us/leadership"
                                textIsRich="true"
                                titleFromPage="false">
                                <cq:responsive jcr:primaryType="nt:unstructured">
                                    <default
                                        jcr:primaryType="nt:unstructured"
                                        offset="0"
                                        width="6"/>
                                    <phone
                                        jcr:primaryType="nt:unstructured"
                                        offset="0"
                                        width="12"/>
                                </cq:responsive>
                                <actions jcr:primaryType="nt:unstructured">
                                    <item0
                                        jcr:primaryType="nt:unstructured"
                                        link="/content/menarini-stemline/en/en/about-us/leadership"
                                        linkTarget="_self"
                                        text="SEE OUR LEADERS"/>
                                </actions>
                            </card_copy_copy>
                            <card_copy
                                jcr:description="&lt;p>Recent news, the news archive, projects, events, and more&lt;/p>&#xd;&#xa;"
                                jcr:lastModified="{Date}2023-04-20T13:12:39.990Z"
                                jcr:lastModifiedBy="m.papini@adiacent.com"
                                jcr:primaryType="nt:unstructured"
                                jcr:title="Latest News"
                                sling:resourceType="menarinimaster/components/card"
                                descriptionFromPage="false"
                                disableLazyLoading="false"
                                fileReference="/content/dam/menarini-stemline/assets/box_home_news_int.jpg"
                                imageFromPageImage="false"
                                isDecorative="true"
                                linkTarget="_blank"
                                linkURL="https://www.menarini.com/en-us/news"
                                textIsRich="true"
                                titleFromPage="false">
                                <cq:responsive jcr:primaryType="nt:unstructured">
                                    <default
                                        jcr:primaryType="nt:unstructured"
                                        offset="0"
                                        width="6"/>
                                    <phone
                                        jcr:primaryType="nt:unstructured"
                                        offset="0"
                                        width="12"/>
                                    <tablet
                                        jcr:primaryType="nt:unstructured"
                                        offset="0"
                                        width="12"/>
                                </cq:responsive>
                                <actions jcr:primaryType="nt:unstructured">
                                    <item0
                                        jcr:primaryType="nt:unstructured"
                                        link="https://www.menarini.com/en-us/news"
                                        linkTarget="_self"
                                        text="EXPLORE THE NEWS"/>
                                </actions>
                            </card_copy>
                            <cq:responsive jcr:primaryType="nt:unstructured">
                                <phone
                                    jcr:primaryType="nt:unstructured"
                                    offset="0"
                                    width="12"/>
                            </cq:responsive>
                            <container_copy_copy_
                                jcr:lastModified="{Date}2023-04-14T07:51:59.318Z"
                                jcr:lastModifiedBy="m.papini@adiacent.com"
                                jcr:primaryType="nt:unstructured"
                                sling:resourceType="menarinimaster/components/container"
                                layout="responsiveGrid">
                                <spacer_copy
                                    jcr:lastModified="{Date}2023-04-14T07:46:43.695Z"
                                    jcr:lastModifiedBy="m.papini@adiacent.com"
                                    jcr:primaryType="nt:unstructured"
                                    sling:resourceType="menarinimaster/components/spacer"
                                    spacer="50"/>
                                <banner_copy_copy_cop
                                    cq:styleIds="[1655107229265]"
                                    jcr:description="&lt;p>The origins of Menarini Group date back to 1886 when Archimede Menarini opened the Farmacia Internazionale in Naples. Today, Menarini Group is present in 140 countries worldwide, a guarantee of internationally recognized quality.&lt;/p>&#xd;&#xa;"
                                    jcr:lastModified="{Date}2023-04-14T07:52:43.358Z"
                                    jcr:lastModifiedBy="m.papini@adiacent.com"
                                    jcr:primaryType="nt:unstructured"
                                    jcr:title="THE MENARINI GROUP STORY"
                                    sling:resourceType="menarinimaster/components/banner"
                                    descriptionFromPage="false"
                                    disableLazyLoading="false"
                                    fileReference="/content/dam/menarini-stemline/assets/placeholders/sample-1920-740.jpg"
                                    imageFromPageImage="false"
                                    isDecorative="true"
                                    linkTarget="_blank"
                                    linkURL="https://www.menarini.com/en-us/about-us"
                                    textIsRich="true"
                                    titleFromPage="false">
                                    <actions jcr:primaryType="nt:unstructured">
                                        <item0
                                            jcr:primaryType="nt:unstructured"
                                            link="https://www.menarini.com/en-us/about-us"
                                            linkTarget="_self"
                                            text="LEARN MORE ABOUT MENARINI GROUP'S HISTORY"/>
                                    </actions>
                                </banner_copy_copy_cop>
                                <cq:responsive jcr:primaryType="nt:unstructured">
                                    <phone
                                        jcr:primaryType="nt:unstructured"
                                        offset="0"
                                        width="12"/>
                                </cq:responsive>
                            </container_copy_copy_>
                        </container_copy_copy>
                    </container_197822381>
                </container>
            </container>
        </root>
        <cq:featuredimage
            jcr:lastModified="{Date}2023-03-10T09:02:55.862Z"
            jcr:lastModifiedBy="m.papini@adiacent.com"
            jcr:primaryType="nt:unstructured"
            sling:resourceType="core/wcm/components/image/v3/image"
            altValueFromDAM="true"/>
    </jcr:content>
</jcr:root>
